San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor from the weight loss drug current market in February immediately after revealing promising knowledge from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection and in M